Thomas Smith
Stock Analyst at Leerink Partners
(4.98)
# 62
Out of 4,457 analysts
680
Total ratings
56.4%
Success rate
50.8%
Average return
Main Sectors:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Initiated Coverage: Buy | $10 | $2.94 | +240.14% | 1 | Jun 22, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | n/a | $13.36 | - | 8 | Jun 12, 2026 | |
| XFOR X4 Pharmaceuticals | Initiated Coverage: Buy | $12 | $4.23 | +183.69% | 1 | Jun 2, 2026 | |
| IRON Disc Medicine | Reiterated: Buy | n/a | $74.50 | - | 27 | Jun 2, 2026 | |
| EQ Equillium | Upgraded: Buy | $6 | $3.08 | +94.81% | 34 | May 28, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | n/a | $9.48 | - | 17 | May 27, 2026 | |
| ALMS Alumis | Reiterated: Buy | $32 | $27.14 | +17.91% | 13 | May 15, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $106 | $90.16 | +17.57% | 1 | Apr 13, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $50 | $18.79 | +166.10% | 39 | Apr 6, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $52 → $50 | $38.53 | +29.77% | 37 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 → $52 | $15.05 | +245.51% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $17.82 | +102.02% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.38 | - | 20 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $12 | $3.51 | +241.88% | 1 | Jan 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $32 | $8.78 | +264.46% | 18 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | kr 102.00 | $34.40 | +196.51% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $118 | $39.54 | +198.43% | 38 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.93 | - | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $5.02 | +39.44% | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $104 → $115 | $96.15 | +19.60% | 17 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $73 → $14 | $19.91 | -29.68% | 32 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $780 | $912.46 | -14.52% | 35 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $37.44 | - | 40 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $527.28 | - | 39 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $7.79 | +233.76% | 15 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.88 | +106.19% | 34 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $10.93 | +220.22% | 52 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $14.14 | n/a | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $17.64 | n/a | 16 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $15.41 | n/a | 28 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $18.63 | n/a | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $4.24 | n/a | 25 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $1.16 | n/a | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $33 | $109.32 | n/a | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.40 | n/a | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $2 | $24.21 | n/a | 16 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 5,304p | $134.00 | n/a | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $21 | $8.17 | n/a | 1 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $6 | $2.23 | n/a | 1 | Sep 8, 2017 |
Altimmune
Jun 22, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $2.94
Upside: +240.14%
Climb Bio
Jun 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.36
Upside: -
X4 Pharmaceuticals
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $4.23
Upside: +183.69%
Disc Medicine
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $74.50
Upside: -
Equillium
May 28, 2026
Upgraded: Buy
Price Target: $6
Current: $3.08
Upside: +94.81%
Cartesian Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.48
Upside: -
Alumis
May 15, 2026
Reiterated: Buy
Price Target: $32
Current: $27.14
Upside: +17.91%
Spyre Therapeutics
Apr 13, 2026
Reiterated: Buy
Price Target: $106
Current: $90.16
Upside: +17.57%
Viridian Therapeutics
Apr 6, 2026
Reiterated: Buy
Price Target: $50
Current: $18.79
Upside: +166.10%
Immunovant
Apr 2, 2026
Reiterated: Buy
Price Target: $52 → $50
Current: $38.53
Upside: +29.77%
Mar 6, 2026
Reiterated: Buy
Price Target: $42 → $52
Current: $15.05
Upside: +245.51%
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $17.82
Upside: +102.02%
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.38
Upside: -
Jan 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $3.51
Upside: +241.88%
Dec 15, 2025
Reiterated: Buy
Price Target: $25 → $32
Current: $8.78
Upside: +264.46%
Nov 26, 2025
Initiated Coverage: Buy
Price Target: kr 102.00
Current: $34.40
Upside: +196.51%
Oct 23, 2025
Reiterated: Buy
Price Target: $118
Current: $39.54
Upside: +198.43%
Oct 21, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.93
Upside: -
Oct 15, 2025
Reiterated: Buy
Price Target: $7
Current: $5.02
Upside: +39.44%
Oct 8, 2025
Reiterated: Buy
Price Target: $104 → $115
Current: $96.15
Upside: +19.60%
Oct 1, 2025
Maintained: Buy
Price Target: $73 → $14
Current: $19.91
Upside: -29.68%
Sep 17, 2025
Reiterated: Buy
Price Target: $780
Current: $912.46
Upside: -14.52%
Aug 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $37.44
Upside: -
Aug 19, 2025
Maintained: Buy
Price Target: n/a
Current: $527.28
Upside: -
Aug 18, 2025
Reiterated: Buy
Price Target: $26
Current: $7.79
Upside: +233.76%
Aug 15, 2025
Reiterated: Buy
Price Target: $8
Current: $3.88
Upside: +106.19%
Aug 7, 2025
Reiterated: Buy
Price Target: $35
Current: $10.93
Upside: +220.22%
Apr 16, 2025
Maintained: Hold
Price Target: n/a
Current: $14.14
Upside: n/a
Aug 28, 2024
Reiterated: Buy
Price Target: $58
Current: $17.64
Upside: n/a
Aug 8, 2024
Maintained: Hold
Price Target: $5
Current: $15.41
Upside: n/a
Aug 8, 2024
Reiterated: Buy
Price Target: $6
Current: $18.63
Upside: n/a
Aug 7, 2024
Reiterated: Buy
Price Target: $7
Current: $4.24
Upside: n/a
Aug 7, 2024
Reiterated: Buy
Price Target: $46
Current: $1.16
Upside: n/a
Aug 7, 2024
Maintained: Hold
Price Target: $33
Current: $109.32
Upside: n/a
Mar 15, 2024
Maintained: Buy
Price Target: n/a
Current: $8.40
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: $13 → $2
Current: $24.21
Upside: n/a
Aug 8, 2022
Maintained: Buy
Price Target: 5,304p
Current: $134.00
Upside: n/a
Jan 17, 2019
Initiated Coverage: Hold
Price Target: $21
Current: $8.17
Upside: n/a
Sep 8, 2017
Initiated Coverage: Hold
Price Target: $6
Current: $2.23
Upside: n/a